Endocrinology, Diabetes & Metabolism Doctors in Collegeville, PA Accepting Medicare

5 Endocrinology, Diabetes & Metabolism doctors found. Showing 1 - 5

Dr. Lisa L Hamaker, M.D. Internal Medicine - Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 100 Market St Ste 300, Collegeville, PA 19426 Phone: 484-622-6401    Fax: 484-622-6403

Sumon Agarwala, MD Internal Medicine - Endocrinology, Diabetes & Metabolism Medicare: Medicare Enrolled Practice Location: 100 Market St Ste 300, Collegeville, PA 19426 Phone: 484-622-6401    Fax: 484-622-6403

Dr. Suzette Y Osei, M.D. Internal Medicine - Endocrinology, Diabetes & Metabolism Medicare: Not Enrolled in Medicare Practice Location: 1250 S Collegeville Rd, Glaxosmith Kline Pharmaceutical, Collegeville, PA 19426 Phone: 610-917-6880    Fax: 610-917-4177

Gayle P Orczyk, M.D. Internal Medicine - Endocrinology, Diabetes & Metabolism Medicare: Not Enrolled in Medicare Practice Location: Wyeth Research, 500 Arcola Road, Collegeville, PA 19426 Phone: 484-865-5567

Vishal Datta, M.D. Internal Medicine - Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 100 Market St Ste 300, Collegeville, PA 19426 Phone: 215-997-9441

News Archive

Free open source hardware could be used to fight against coronavirus

Free open source hardware and 3D printing could help to alleviate the burden of Covid-19 on global health systems, according to scientists at the University of Sussex.

CREON Delayed-Release Capsules improves fat absorption in patients with Cystic Fibrosis

Solvay Pharmaceuticals, Inc. announced that Phase III data published in the Journal of Cystic Fibrosis showed that CREON® (pancrelipase) Delayed-Release Capsules, the most prescribed pancreatic enzyme replacement therapy (PERT) in the United States, significantly improves a key measure of fat absorption in patients with CF who suffer from exocrine pancreatic insufficiency (EPI).

RHUCIN clinical trial results published in JACI journal

Santarus, Inc., a specialty biopharmaceutical company, today announced the publication of an integrated analysis of two randomized placebo-controlled clinical trials with RHUCIN (recombinant human C1 inhibitor, or rhC1INH), in the October issue of the peer reviewed Journal of Allergy and Clinical Immunology (JACI).

Mayo's decision to limit patients makes it a poor model, critics say

The Mayo Clinic has started limiting the number of Medicare and Medicaid patients it admits and critics argue that such restrictions have made Mayo too selective to serve as a model for health-care reform.

Read more Medical News

› Verified 7 days ago